108.52
2.56 (2.42%)
| Penutupan Terdahulu | 105.96 |
| Buka | 106.01 |
| Jumlah Dagangan | 1,571,717 |
| Purata Dagangan (3B) | 2,674,420 |
| Modal Pasaran | 14,093,972,480 |
| Harga / Jualan (P/S) | 14.47 |
| Harga / Buku (P/B) | 55.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Oct 2025 |
| Margin Keuntungan | -53.82% |
| Margin Operasi (TTM) | -54.33% |
| EPS Cair (TTM) | -3.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 20.80% |
| Nisbah Semasa (MRQ) | 4.11 |
| Aliran Tunai Operasi (OCF TTM) | -272.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -67.71 M |
| Pulangan Atas Aset (ROA TTM) | -18.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -4,584.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Bercampur |
| Diagnostics & Research (Global) | Menaik | Bercampur | |
| Stok | Guardant Health, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.63 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.53% |
| % Dimiliki oleh Institusi | 97.57% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 130.00 (Morgan Stanley, 19.79%) | Beli |
| Median | 80.00 (-26.28%) | |
| Rendah | 67.00 (Guggenheim, -38.26%) | Beli |
| Purata | 86.00 (-20.75%) | |
| Jumlah | 16 Beli | |
| Harga Purata @ Panggilan | 75.46 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 02 Dec 2025 | 130.00 (19.79%) | Beli | 103.87 |
| BTIG | 30 Oct 2025 | 100.00 (-7.85%) | Beli | 92.41 |
| 25 Sep 2025 | 80.00 (-26.28%) | Beli | 60.18 | |
| Barclays | 30 Oct 2025 | 85.00 (-21.67%) | Beli | 92.41 |
| 02 Oct 2025 | 70.00 (-35.50%) | Beli | 61.46 | |
| Canaccord Genuity | 30 Oct 2025 | 100.00 (-7.85%) | Beli | 92.41 |
| 26 Sep 2025 | 75.00 (-30.89%) | Beli | 60.03 | |
| Citigroup | 30 Oct 2025 | 100.00 (-7.85%) | Beli | 92.41 |
| Evercore ISI Group | 30 Oct 2025 | 90.00 (-17.07%) | Beli | 92.41 |
| 07 Oct 2025 | 68.00 (-37.34%) | Beli | 63.44 | |
| UBS | 30 Oct 2025 | 110.00 (1.36%) | Beli | 92.41 |
| 25 Sep 2025 | 80.00 (-26.28%) | Beli | 60.18 | |
| Piper Sandler | 22 Oct 2025 | 90.00 (-17.07%) | Beli | 68.03 |
| Guggenheim | 25 Sep 2025 | 67.00 (-38.26%) | Beli | 60.18 |
| JP Morgan | 25 Sep 2025 | 70.00 (-35.50%) | Beli | 60.18 |
| Leerink Partners | 25 Sep 2025 | 75.00 (-30.89%) | Beli | 60.18 |
| Mizuho | 25 Sep 2025 | 70.00 (-35.50%) | Beli | 60.18 |
| Stifel | 25 Sep 2025 | 70.00 (-35.50%) | Beli | 60.18 |
| TD Cowen | 25 Sep 2025 | 72.00 (-33.65%) | Beli | 60.18 |
| Wolfe Research | 25 Sep 2025 | 75.00 (-30.89%) | Beli | 60.18 |
| Wells Fargo | 22 Sep 2025 | 72.00 (-33.65%) | Beli | 59.78 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MIGNONE ROBERTO | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MIGNONE ROBERTO | Pengarah | 21 Nov 2025 | Pelaksanaan pilihan | 264 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |